Invention Grant
US07972600B2 IGF-IR antagonists as adjuvants for treatment of prostate cancer
有权
IGF-1R拮抗剂作为治疗前列腺癌的佐剂
- Patent Title: IGF-IR antagonists as adjuvants for treatment of prostate cancer
- Patent Title (中): IGF-1R拮抗剂作为治疗前列腺癌的佐剂
-
Application No.: US11702838Application Date: 2007-02-05
-
Publication No.: US07972600B2Publication Date: 2011-07-05
- Inventor: Dale L. Ludwig , Stephen R. Plymate
- Applicant: Dale L. Ludwig , Stephen R. Plymate
- Applicant Address: US NY New York US WA Seattle
- Assignee: ImClone LLC,University of Washington
- Current Assignee: ImClone LLC,University of Washington
- Current Assignee Address: US NY New York US WA Seattle
- Agent Nicole S. Woods; Sanjay Jivraj
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K47/48 ; A61K31/517 ; C07K16/00 ; C07K16/28
Abstract:
The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.
Public/Granted literature
- US20090175868A1 IGF-IR antagonists as adjuvants for treatment of prostate cancer Public/Granted day:2009-07-09
Information query
